Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BEAT

BioTelemetry (BEAT) Stock Price, News & Analysis

BioTelemetry logo

About BioTelemetry Stock (NASDAQ:BEAT)

Advanced Chart

Key Stats

Today's Range
$2.17
$2.40
50-Day Range
$71.46
$72.27
52-Week Range
$27.35
$73.10
Volume
215,243 shs
Average Volume
117,297 shs
Market Capitalization
$59.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

BioTelemetry Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
32nd Percentile Overall Score

BEAT MarketRank™: 

BioTelemetry scored higher than 32% of companies evaluated by MarketBeat, and ranked 806th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioTelemetry has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioTelemetry has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioTelemetry's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioTelemetry is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioTelemetry is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioTelemetry has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.88% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 26.69%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioTelemetry does not currently pay a dividend.

  • Dividend Growth

    BioTelemetry does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.88% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 26.69%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 1 people have searched for BEAT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioTelemetry insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.85% of the stock of BioTelemetry is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.77% of the stock of BioTelemetry is held by institutions.

  • Read more about BioTelemetry's insider trading history.
Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.

BEAT Stock News Headlines

“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
HeartBeam Reports Third Quarter 2024 Results
See More Headlines

BEAT Stock Analysis - Frequently Asked Questions

BioTelemetry, Inc. (NASDAQ:BEAT) posted its earnings results on Wednesday, August, 14th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.03.

BioTelemetry (BEAT) raised $16 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioTelemetry investors own include NVIDIA (NVDA), Meta Platforms (META), Bristol-Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), PayPal (PYPL) and AbbVie (ABBV).

Company Calendar

Last Earnings
8/14/2024
Today
1/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAT
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+257.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.61 per share

Miscellaneous

Free Float
21,105,000
Market Cap
$59.74 million
Optionable
Not Optionable
Beta
-0.83
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:BEAT) was last updated on 1/5/2025 by MarketBeat.com Staff
From Our Partners